The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026.
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. mylan stock buy or sell
Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors. The company is focusing on higher-margin generic launches
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues. mylan stock buy or sell
No account yet?
Create an Account
